Tag: 6

Stjórn Reita hf. samþykkti nýja endurkaupaáætlun félagsins þann 8. apríl 2026 sbr. tilkynningu í Kauphöll þann dag. Var henni hrint í framkvæmd þann 9. apríl 2026. Endurkaupaáætlunin er framkvæmd í samræmi við ákvæði hlutafélagalaga nr. 2/1995, 5. gr. reglugerðar Evrópuþingsins og ráðsins (ESB) um markaðssvik nr. 596/2014, sem og framselda reglugerð framkvæmdastjórnarinnar 2016/1052, samanber lög um aðgerðir gegn markaðssvikum nr. 60/2021.

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido^®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

(Fornebu, 8. juni 2026) Konkurransetilsynet har godkjent Telenors kjøp av GlobalConnects norske fibervirksomhet for privatkunder. Transaksjonen er verdsatt til 6 milliarder kroner og godkjennes på vilkår av avhjelpende tiltak.

Casino Group and the Zouari Family strengthen their historic partnership to accelerate in convenience retail